Clinical trial NCT04525209: Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma
Official title: Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2020-08-25
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Chinese PDAC patients

Brief summary: A large-scale, high-throughput, multi-dimensional comprehensive study of PDAC multiomics will be carried out. In this study, clinical specimens of resected PDAC collected by our research group from 2017 to 2019 will be selected as research objects.Tumor tissues and their adjacent non-tumor tissues from more than 200 PDAC patients are expected to be used for genome, transcriptome sequencing and mass spectrometry analysis of proteome and phosphorylated proteome.Combined with the data results of multiomics, bioinformatics analysis and network database information, we will clarify the relationship between multiomics of pancreatic cancer and established the new subtyping of pancreatic cancer proteome. A molecular landscape of the progression of pancreatic cancer at the genome-transcriptome-proteome level provides new therapeutic targets to improve the prognosis of this deadly disease.


Eligibility criteria: Inclusion Criteria:

1. The diagnosis of pancreatic cancer was confirmed by histological examination or fine needle aspiration cytology;
2. The tumor was graded according to THE WHO standard, and the tumor stage was graded according to the TNM stage;

Exclusion Criteria:

1. The inclusion criteria of the above groups were not met;
2. There are few tissue specimens, only enough for clinical diagnosis;
3. Patients are unwilling to conduct follow-up study;
4. For the new diagnosed patient, radiotherapy or chemotherapy have been given in the previous three months;

Primary outcomes:
measure: Integrative Proteomic Characterization of PDAC
timeFrame: Two yeaers
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: RUIJIN Hospital
state: Shanghai
Study officials:
affiliation: Ruijin Hospital
name: Hao Chen, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gao Q, Zhu H, Dong L, Shi W, Chen R, Song Z, Huang C, Li J, Dong X, Zhou Y, Liu Q, Ma L, Wang X, Zhou J, Liu Y, Boja E, Robles AI, Ma W, Wang P, Li Y, Ding L, Wen B, Zhang B, Rodriguez H, Gao D, Zhou H, Fan J. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell. 2019 Oct 3;179(2):561-577.e22. doi: 10.1016/j.cell.2019.08.052.
citation: Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu; Cancer Genome Atlas Research Network. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017 Aug 14;32(2):185-203.e13. doi: 10.1016/j.ccell.2017.07.007.